ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis

Permanent link
https://hdl.handle.net/10037/10528
DOI
https://doi.org/10.1007/s10549-016-4002-x
Thumbnail
View/Open
article.pdf (1013.Kb)
Main article (PDF)
Date
2016-10-05
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Stub, Trine; Hervik, Jill Brook
Abstract
Purpose: To access frequency and severity of adverse effects (AE) of non-hormonal drugs (NHD) for hot flashes in breast cancer survivors compared to controls and analyze adverse-effect risk by reviewing published randomized trials.

Methods: Cochrane Central Register for Controlled Trials, Embase, Medline, PsycINFO and PubMed databases were searched. Trials were included where participants were survivors of breast cancer suffering from hot flashes, treatment included self-administered venlafaxine, gabapentin or clonidine, and AE were reported. AE frequency and severity were graded. A meta-analysis of ten trials with sub-group analyses was conducted.

Results: Forty-nine studies were identified, and 12 were included. A total of 1467 participants experienced 772 adverse effects, 81 % (n = 627) in the treatment group and 19 % (n = 145) in the control group. Sixty-seven percent of AE was graded as mild and 33 % as moderate. The frequency of AE for NHD was overall significant compared to placebo. Sub-group analysis indicated that AE frequency and severity increased at higher doses of venlafaxine and gabapentin compared to placebo.

Conclusion: The odds for experiencing AE was significantly higher in patients randomized to high-dose NHD than those randomized to controls, including placebo, lowdose medication and acupuncture. These therapies should be considered as a potential treatment alternative.

Description
Published version. Source at http://dx.doi.org/10.1007/s10549-016-4002-x
Publisher
Springer
Citation
Hervik, J. B., Stub, T.: Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis. Breast Cancer Research and Treatment. 2016;160(2):223-236
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (samfunnsmedisin) [1516]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)